Moderna stock is up more than 600% this year and still climbing
The vaccine maker's stock gained 18% last week after a report on a planned NIH cancer vaccine initiative and its addition to the Nasdaq-100
We haven't written up this one. Quartz has the full story — the link below goes straight to it.